|
TWST: We would like to begin with a brief historical sketch of Chindex
and a picture of the things you are doing at the present time.
Mr. Pemble: Chindex has been active in the healthcare markets in China
for over 25 years. We have been a US public company since 1993 and
operate in two specific sectors of the Chinese healthcare market, the
first being private hospitals. We own and operate two private
facilities, one in Beijing and one in Shanghai, and these are primary
care facilities with affiliated satellite clinics. The second business
that we do is distribution nationwide of various types of medical
equipment, capital equipment and consumable supplies, both imported into
China from the US, Germany and elsewhere, and also distributed in China
locally through a distribution logistics platform that we have developed
over the last several years. These are two areas of business that we are
continuing to grow and to find very dynamic and exciting in China,
particularly the private healthcare services. Our hospital network has
being growing quite rapidly over the last several years. TWST: Who do you serve primarily in the hospitals?
Mr. Pemble: Our patient mix is segmented in both Beijing and Shanghai
into the expatriate business and diplomatic communities and the affluent
sectors of the local Chinese community. The initial market penetration
in both markets ' in Beijing and Shanghai ' was in the expatriate
market. Our longer-term strategy is to market and continue to access an
increasingly large percentage of the local Chinese community, which is
obviously quite substantial in both of those places. Our future United
Family Hospital development in Xiamen and in other places in China will
be on a much more local market basis, and we find that the local Chinese
markets are quite receptive to the quality of care that we are able to
provide through our United Family Hospital system.
Tickers included in this excerpt: CHDX
For more information call (212) 952 7433. The
Wall Street Transcript does not endorse any of the comments made by interviewees, and does
not make stock recommendations.
|
|
